Evidence mapPaperPMID 40905271Full record

ArticleInquiry : a journal of medical care organization, provision and financing

The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to 2022.

Neal Masia, James D Motyka, Kimberly Westrich, Jon D Campbell

Erratum issuedAbstract read
In one paragraph

Article in Inquiry : a journal of medical care organization, provision and financing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Neal MasiaHealth Capital Group, LLC and Columbia University, New York, NY, USA.ORCID 0009-0007-2438-6058
James D MotykaNational Pharmaceutical Council, Washington, DC, USA.ORCID 0009-0006-9216-0141
Kimberly WestrichNational Pharmaceutical Council, Washington, DC, USA.
Jon D CampbellNational Pharmaceutical Council, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We tested whether the 340B program impacts Affordable Care Act (ACA) premiums. Data from 2018 to 2022 was used to establish a baseline for silver benchmark premiums and other key measures, including: the number of active 340B sites per 10,000 people in a county (Hospital Site Density, or HSD), ACA benchmark plan premiums for every county, and measures likely to influence insurance premiums including per capita income, unemployment, and hospital market power. We used a multivariate fixed effects regression that included state and year effects, the explanatory variables, and the county-level HSD for each year. The impact of 340B on ACA premiums was illustrated using 2022 data. We estimate that a 1-unit change in 340B HSD was associated with a 1.1% (95% CI 0.73-1.15) change in the benchmark ACA premium. In 2022, the mean county 340B HSD was 1.63, and the mean Silver Benchmark Plan monthly premium was $500. After adjusting for per capita income, hospital concentration index, and other factors, the mean 340B HSD accounted for 1.8% (95% CI: 1.3-2.1) of the average Silver Benchmark Plan monthly premium, or $8.90 (95% CI $6.50-$10.25) per month, implying a cost in additional subsidies of over $106 per year per subsidized ACA enrollee. The results support that the 340B program is associated with a financially meaningful component of ACA premiums.

Indexed as

Insurance, HealthPatient Protection and Affordable Care ActBenchmarkingHumansLongitudinal StudiesUnited States340BAffordable Care Act (ACA)health insurancehealth policy researchpremiums

Identifiers

PMID40905271
PMCPMC12411698

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.